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Abstract
Background: The health-related quality of life (HRQL) is an important indicator of the burden of
musculoskeletal disease. The Medical Outcome Study Short-Term 36 (SF-36) is the most used tool that
evaluates HRQL as a subjective perception about psychological and physical limitations due to an
underlying illness. The purpose of this study was to compare the HRQL scores among patients with
rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) and a selected sample
of health people and determine their relationship with measures of clinical condition.
Methods: 799 patients (469 with RA, 164 with AS, 65 with axial PsA and 101 with peripheral PsA)
accepted the invitation to participate. 1579 healthy controls were used for the comparison. We calculated
scores for the eight SF-36 subscales, the Physical Component Summary (PCS) score, and the Mental
Component Summary (MCS) score, according to published algorithms. Disease-related characteristics
included disease duration, comorbidity, a measure for disease activity and for radiographic damage. The
presence of comorbidity was ascertained through patient's self-reports by the Self-Administered
Comorbidity Questionnaire (SCQ). Comparison were performed with respect to sex and age, and s-
scores were calculated for comparison with the norm. Multivariate analyses were used to assess the
relationship between HRQL and radiographic damage, disease activity, and socio-demographic data.
Results: The four inflammatory rheumatic diseases (IRD), compared to controls, significantly impaired all
eight health concepts of the SF-36 (p < 0.0001) in both component PCS and MCS scores (p < 0.0001).
Overall, the dimensions typically affected were physical functioning, limitations due to physical function,
and bodily pain. The disease with the worst HRQL for those dimensions was RA. The multivariate analyses
revealed that the physical component was influenced by a high disease activity and comorbidity. The
severity of psoriatic lesions was associated with poor mental functioning in patients with PsA.
Conclusion: Chronic IRD have a clearly detrimental effect on the HRQL in both sex and in age groups,
and physical domain is more impaired than mental and social ones.
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Background
Rheumatoid arthritis (RA), ankylosing spondylitis (AS),
and psoriatic arthritis (PsA) are three common types of
inflammatory rheumatic diseases (IRD) associated with
deformities and joint destruction. RA is the most frequent
IRD, with a prevalence of 0.5% [1]. Patients with active RA
have been shown to suffer deficits in health-related qual-
ity of life (HRQL) along a number of physical functioning
and mental health dimensions [2,3]. Furthermore,
patients with RA who have significant functional disabil-
ity have a 3-fold increased risk of mortality compared with
that of the general population [4]; this risk is comparable
with that of individuals of the general population in the
highest quintile for systolic and diastolic blood pressure,
cholesterol level, or pack-years of smoking [5]. AS is a sys-
temic and IRD predominantly affecting the axial skeleton
with sacroiliac joint involvement as its hallmark, causing
decreased spinal mobility [6]. Similarly to other chronic
diseases, AS can affect quality of life, morbidity, mortality,
participation in paid and unpaid work, and healthcare
costs [7-9]. PsA is an inflammatory peripheral and/or
axial arthritis associated with psoriasis, usually seronega-
tive for rheumatoid factor [10]. In addition to the periph-
eral joint disease, patients with PsA have a debilitating
skin disease, and up to 50% may also have spinal disease
[11]. Compared to RA and AS, there is less information
about the burden of illness in PsA. Although considered a
benign disease in the majority of cases given in previous
reports or in population-based samples [12]. clinical
cohort studies described PsA as a progressive, disabling
disease, particularly when polyarticular peripheral arthri-
tis is present [10,11,13]. Thus, IRD represents a tremen-
dous economic burden, not only for patients and their
families, but also for society as a whole.
Traditional methods of evaluation, with a focus on the
locomotor system and measures of impairment, may fail
to describe the extensive multi-dimensional issues associ-
ated with chronic rheumatic conditions. Consideration of
HRQL has become increasingly important in decisions
regarding resource allocation, intervention design, and
pharmacological treatment with biologic agents of indi-
viduals with chronic inflammatory disabling conditions
[14-16]. Two broad approaches to measuring patient per-
ceptions of HRQL can be described: generic instruments
that provide a broad summary of HRQL, and specific
instruments that focus on issues of relevance to a specific
disease or patient group. Generic instruments are not age-
, disease- or treatment specific, and contain multiple
HRQL concepts of relevance to patients and the general
population, supporting application in both populations
[17]. The Short Form 36-item Health Survey Question-
naire (SF-36) is a widely used example of a generic health
profile [18]. The items cover eight domains of HRQL,
including physical and social functioning and mental
health.
The main objective of this study was to examine the self-
reported health status in patients with RA, AS and PsA,
compared with a selected sample of health people. Fur-
thermore, we wanted to explore the associations between
health status and age, sex of the patients, and educational
level in these IRD and to estimate the burden of the dis-
ease by controlling for the normal variations in health sta-
tus in the general population.
Methods
Patients
Participants at this study are part of an ongoing longitudi-
nal project measuring rheumatic disease outcomes,
approved by the local Ethical Committee for Medical
Research. Consecutive adult rheumatic disease patients
from the Rheumatology Clinic of the Università Politec-
nica delle Marche, who agreed to participate in the study,
completed an informed consent form. The study popula-
tion includes patients examined by two rheumatologists
and fulfilling the American College of Rheumatology
(ACR) classification criteria for RA [19], the modified New
York criteria for AS [20], and the European Spondylar-
thropathy Study Group (ESSG) preliminary criteria for
PsA [21]. For the purposes of the present study, AS
patients with peripheral articular involvement were
excluded. Peripheral involvement was defined as synovitis
of at least one large joint (wrist, elbow, shoulder, hip,
knee, ankle) or three or more small joints (hands, feet,
sternoclavicular joints) [7]. The diagnoses of PsA are
recorded with a thesaurus specific for the database. Two
terms for PsA have been used: "predominantly peripheral
arthritis with psoriasis" (in this report: peripheral PsA)
and "predominantly spondarthritis with psoriasis" (axial
PsA) [22]. The distinction was made by each treating rheu-
matologist according to their clinical judgment. Patients
with rheumatoid factor positivity and with symmetrical
polyarthritis who satisfied the ACR classification criteria
for RA were excluded. Information on the presence of pso-
riasis in familial subjects was also obtained, especially in
patients who had features of spondyloarthritis, such as
enthesitis. Of the 1121 patients with IRD invited to
undergo a complete medical history, a careful clinical
examination and radiological evaluation, 799 (71.3%)
patients (469 with RA, 164 with SA, 65 with axial PsA and
101 with peripheral PsA) accepted the invitation to partic-
ipate by completing the questionnaires and the physical
and radiological evaluation. For comparison, data from a
previous cross-sectional population-based study, namely
MAPPING (MArche Pain Prevalence INvestigation
Group) Study will be used. This study design has been
described in detail elsewhere [1]. The sample reflects the
age/sex related stratification/distribution of the Italian
population. Briefly, the MAPPING study was conducted
on 4000 subjects aged 18 years and over, selected from the
practice lists of 16 general practitioner-GPs (total target
adult population of 20882 individuals). These GPs wereHealth and Quality of Life Outcomes 2009, 7:25 http://www.hqlo.com/content/7/1/25
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representative of the practices in Marche in terms of size
of practice, geographical location, and socio-economic
status of those attending. The sample for the survey was
selected randomly so that there would be equal numbers
from each of the age-sex bands (five age-groups ranging
from 18–34 years to 75 years and over) and was weighted
to ensure an equal representation of patients in each of
the subgroups. A total of 336 individuals were excluded
through this procedure: 43 individuals had left the prac-
tice, 49 had dementia or mental illness, 31 were termi-
nally ill, 114 had died, and 99 individuals had no reason
given. The remaining 3664 individuals were sent a stand-
ardized self-completion postal questionnaire. Subjects
who did not return their questionnaires within three
weeks were sent another questionnaire to maximise the
response rate. The patients were instructed to complete all
the questionnaires at home and to return them in a pre-
paid envelope. To increase the response rate the nonre-
sponders were contacted by telephone and encouraged to
return the questionnaires. Of 3470 questionnaires deliv-
ered (194 participants could not be contacted because of
unknown address or recent death, absent from the com-
munity during the survey, hospitalization etc.), 2155 were
returned after two postal reminders, which gave a
response rate of 62.1%. Of these 2155 people who com-
pleted the questionnaires, 576 subjects were diagnosed as
having had rheumatic disease at the time of the study [1].
The data collected from the remaining 1579 health con-
trols were used in this study.
Demographics, disease-related characteristics, quality of 
life assessment, and radiographic scoring methods
A comprehensive questionnaire package including socio-
demographic data, quality of life items, and disease-
related variables was administered to the patients. The
socio-demographic variables were age, sex, and highest
attained level of education (primary; secondary; high
school/university). Disease-related characteristics
included disease duration (years since fulfilment of the
classification criteria of the IRD), comorbidity, a measure
for disease activity and for radiographic damage. The Dis-
ease Activity Score (DAS) [23] was used to evaluate disease
activity in patients with RA and peripheral PsA and the
Bath Ankylosing Spondylitis Disease Activity index (BAS-
DAI) [24] was used for patients with AS and axial PsA.
DAS has been developed to provide a measure of RA dis-
ease activity that is more informative than the several dis-
ease activity variables individually [23]. The DAS
combines information from the Ritchie articular index; a
44-joint swollen joint count, erythrocyte sedimentation
rate, and a general health assessment on a visual analog
scale (VAS) [23]. Disease activity in patients with AS and
axial PsA was measured with the BASDAI [24]. The BAS-
DAI consists of 6 VAS relating to major symptoms relevant
to AS: fatigue, spinal pain, joint pain, localized tender-
ness, and morning stiffness (measured in terms of both
degree and length of time stiffness persists). The BASDAI
items range from none (0) to very severe (100) symptoms
[24]. The mean score of 5 items (mean of the 2 morning
stiffness items plus the 4 remaining items) is applied as an
estimate of disease activity. Information about HRQL was
obtained with a validated Italian translation of the self-
administered SF-36 (IQOLA SF-36 Italian Version 1.6)
[25]. The SF-36 contains 36 items, organized into eight
scales covering the dimensions physical functioning (PF),
role limitations due to physical function (RP), bodily pain
(BP), general health (GH), mental health (MH), role lim-
itations due to emotional health (RE), social functioning
(SF), and vitality (VT). One additional item pertains to
health transition [18]. The raw scores were coded and rec-
alibrated following the standard guidelines, and the items
were then summed and transformed to the eight 0–100
scales (0 = worst health, 100 = best health) [18]. On the
basis of these separate subscales, component summary
scores can be calculated to provide a global measure of
physical (PCS) and mental functioning (MCS) [26]. The
PCS and MCS scores range from 0–100, with higher scores
indicating better health [26]. Radiographic damage was
assessed, by a single radiologist (MC) who was unaware of
patient identity, using three different scoring methods.
Radiographs of the hands and feet were assessed in RA
patients, using the modified Sharp/van der Heijde
method [27]. Inter-observer agreement was tested by a
second investigator (FS) on 20 sets of radiographs and the
intra-class correlation coefficient between the two investi-
gators was 0.91. The Sharp van der Heijde modified scor-
ing method [28] was used for assessing erosions and joint
space narrowing of joints of hands and feet in peripheral
PsA. The proposed adapted scoring method for PsA is a
detailed scoring method evaluating erosions, joint space
narrowing, (sub)luxation, ankylosis, gross osteolysis, and
pencil in cup phenomena. The modified Stoke Ankylosing
Spondylitis Spine Score (mSASSS) [29] scoring system
was used to analyse the conventional x-ray findings in
patients with AS and with axial PsA. The mSASSS offers
advantages in measurement properties and is the most
appropriate method by which assessing progression of
structural damage in AS [30]. The severity of psoriatic
lesions was also assessed, using the Psoriasis Area and
Severity Index (PASI) [31]. The PASI is a composite score
used to evaluate the severity of psoriatic lesions by assess-
ing the extent of skin involvement, erythema, plaque
thickness, and degree of scaling [31]. The PASI score can
vary in increments of 0.1 units from 0 to 72, with higher
scores representing a greater degree of psoriatic severity.
Finally, the presence of comorbidity was ascertained
through patient's self-reports using the Self-Administered
Comorbidity Questionnaire (SCQ) [32], an efficient
method to assess comorbid conditions in clinical and
health services research. The SCQ is short, easily under-Health and Quality of Life Outcomes 2009, 7:25 http://www.hqlo.com/content/7/1/25
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stood, and can be completed by individuals without any
medical background. It also allows the subject to note the
severity of each comorbid condition and their perception
of its impact on their function. Because there are 12
defined medical problems and 3 optional conditions (1
point for the presence of the problem, another point if he/
she receives treatment for it, and an additional point if the
problem causes a limitation in functioning) the maxi-
mum score totals 36 points are used [32].
Statistical analysis
The data were analysed using the SPSS version 11.0 (SPSS
Inc, Chicago, IL), and MedCalc®, version 9.2 for Windows
XP. Descriptive statistics are given as means and standard
deviations (SD) for continuous data or as percentages for
counts. Comparisons between groups were performed
with chi-square tests for categorial variables and analysis
of variance (ANOVA) for continuous variables. Standard-
ized difference scores (the s-score or normal score) were
also calculated by subtracting the mean scores of the
patients from the mean scores of the general population,
followed by the division of these deviations by each
scale's standard deviation in the general population. The
standardized s-score is a rescaled score with a population
average of 0 and a standard deviation of 1. The values of
the s-scores were interpreted according to Cohen's effect
size index, in which 0.2 refers to a small difference, 0.5 to
a moderate difference, and 0.8 or more to a large differ-
ence [33]. A set of multivariable analyses were constructed
to adjust for factors potentially associated with poor
HRQL in the four IRD groups. Covariates chosen a priori
included sex (as a dichotomous variable; 0 = male; 1 =
female); age (as a continuous variable); disease duration
(years from disease onset as a continuous variable); edu-
cational level (years of education as a continuous varia-
ble); and the average score of the SCQ questionnaire
(SCQ score as a continuous variable). All these factors
were then introduced as covariates in multiple regression
models in which PCS and MCS SF-36 scores were depend-
ent variables. All variables were entered simultaneously.
Owing to multiple comparisons with increasing risk of
type 1 errors, the level of statistical significance was set at
0.01.
Results
Demographic and clinical data
Demographics and disease characteristics of patients and
healthy controls enrolled in the study are shown in Table
1. There was no significant difference in the demographics
and disease characteristics of those completing (799
patients) and refusing to complete the questionnaires and
the clinical and radiological evaluation (322 patients),
and no significant difference in the proportions of men
and women. As expected, our RA patients were older and
predominantly female, whereas AS patients were younger
and predominantly male, respect to the general popula-
tion. The age and sex distributions of the patients with RA
and PsA and those with AS are significantly different (p <
0.001). Slightly more than one quarter of the patients
with RA, more than two thirds of the patients with AS, and
slightly less than an half of the patients with PsA (44.6
with peripheral PsA and 49.3 with axial PsA) were male.
The onset of AS is typically earlier than RA; therefore, in
older age-matched healthy controls, the patients with AS
will have a longer disease duration than those with RA or
PsA. The educational level among patients with RA was
lower than among patients with AS and PsA (p < 0.01).
Approximately, more than an half of our chronic IRD
patients reported some comorbidity (hypertension, heart
diseases, gastrointestinal conditions, and chronic respira-
tory diseases were the 4 most prevalent comorbidities).
Statistically significant differences were found for a
number of comorbid conditions (p < 0.001) and average
score of the SCQ questionnaire (p < 0.001). Compared
with the general population, significantly higher preva-
lence estimates were observed with respect to cardiovascu-
lar disorders (p < 0.001), chronic pulmonary disease (p <
0.01), and gastrointestinal diseases (p < 0.001).
Self-reported health status results
Scores for respondents with IRD significantly impaired all
eight health concepts of the SF-36 (p < 0.0001) and in
both component summary scores (PCS and MCS) (p <
0.0001), compared with their non-arthritic counterparts
(Table 2). Generally, respondents with IRD report rela-
tively greater deficits in the scales that primarily measure
functional disability, i.e., physical functioning, role limi-
tations due to physical function, bodily pain, general
health, rather than the scales measuring a construct of
mental health, i.e., mental health, role limitations due to
emotional health, social functioning, and vitality. The SF-
36 scores decreased (indicating a linear decline in HRQL),
especially in the physical dimension, with increasing age
in all categories of IRD (Table 3). However, HRQL is
affected by even in the general population (Table 3). Sig-
nificant differences were found between men and women
only in AS group concerning role limitations due to phys-
ical function (p = 0.011), and for general health (p =
0.031), with women reporting worse health than men. No
differences were found for the remaining scales. Addition-
ally, patients and controls with high education level
reported better health on all subscales of the SF-36 than
less educated groups (Table 4). Figure 1 compares the
scores in each domain of the SF-36 health survey for the
study population to age-adjusted general population
norms. The scores for every domain of the SF-36 health
survey were lower for the study population than the corre-
sponding age-adjusted norms (Table 2). The quality of life
patterns for the different IRD, expressed as standardized s-
scores (the difference in the number of standard devia-Health and Quality of Life Outcomes 2009, 7:25 http://www.hqlo.com/content/7/1/25
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tions from the population mean), are shown in Figure 2.
Overall, the dimensions typically affected by IRD were
physical functioning, limitations due to physical function,
and bodily pain. The disease with the worst HRQL for
those dimensions was RA. The mean PCS score of RA
patients was 32.5 (SD = 5.9). The mean MCS score of
patients was 39.4 (SD = 11.8). Regarding the HRQL
dimensions involving mental health problems, patients
with PsA (both peripheral and axial PsA) score generally
lower than the health controls. In patients with AS the
physical domain due to role function-physical aspect and
bodily pain is more impaired than the mental one.
Factors associated with poor health-related quality of life
Multiple regression models were constructed to adjust for
factors potentially associated with poor HRQL in the four
IRD groups. Covariates chosen a priori included the demo-
graphic variables, disease related characteristics and the
and average score of the SCQ questionnaire. All these fac-
tors were introduced as covariates in multiple regression
models in which PCS and MCS SF-36 summary scores
(instead of a single subscale) were dependent variables.
The physical component of the SF-36 was influenced by a
high disease activity (measured by DAS) and chronic
comorbidity (both at a p level < 0.0001), and by radio-
Table 1: Characteristics of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and the 
general population (healthy controls)
Rheumatoid arthritis
(n = 469)
Ankylosing spondylitis
(n = 164)
Peripheral
psoriatic arthritis
(n = 101)
Axial
psoriatic arthritis
(n = 65)
General population
(n = 1579)
Women (%) 71.8 18.9 61.4 50.7 50.2
Age (years)
- mean (± SD) 57.5 (14.3) 51.7 (9.2) 60.7 (11.6) 58.2 (10.3) 55.2 (19.2)
Disease duration
- mean (± SD) 6.1 (4.2) 8.2 (4.6) 7.5 (5.3) 8.4 (4.3) NA
Educational level, n (%)
- primary school 240 (51.2) 70 (42.7) 45 (44.6) 30 (46.1) 928 (58.8)
- secondary school 149 (31.8) 65 (39.6) 43 (42.6) 25 (38.5) 418 (26.5)
- high school/university 80 (17.0) 29 (17.7) 13 (12.8) 10 (14.4) 233 (14.7)
No of comorbid conditions, n (%)
- none 217 (46.3) 73 (44.5) 45 (44.6) 19 (29.3) 548 (34.7)
- 1 131 (27.9) 37 (22.6) 26 (25.7) 12 (18.5) 334 (33.5)
- 2 47 (10.0) 30 (18.3) 13 (12.9) 21 (32.3) 112 (7.1)
- 3 20 (4.3) 15 (9.1) 15 (14.8) 10 (15.4) 69 (4.4)
- 4 25 (5.3) 6 (3.7) 2 (2.0) 2 (3.0) 21 (1.3)
- 5 or more 29 (6.2) 3 (1.8) 0 (0) 1 (1.5) 12 (0.8)
Comorbidity score by SCQ 4.35 (3.1) 2.48 (1.9) 3.75 (2.5) 3.34 (2.1) 1.95 (1.9)
- mean (± SD)
DAS
- mean (± SD) 4.5 (0.8) -- 4.4 (0.9) -- NA
BASDAI -- 54.7 (17.2) -- 53.8 (14.4) NA
- mean (± SD)
Rx Sharp score 59.4 (32.9) -- 62.1 (39.1) -- NA
- mean (± SD)
mSASSS
- mean (± SD) -- 14.7 (5.2) -- 13.7 (5.1) NA
PASI
- mean (± SD) -- -- 7.1 (3.3) 6.7 (2.9) NA
NA = non applicable
Abbreviations: DAS = Disease Activity Score; BASDAI = Bath Ankylosing Spondylitis Disease Activity index; mSASSS = modified Stoke Ankylosing 
Spondylitis Spine Score; PASI = Psoriasis Area and Severity IndexHealth and Quality of Life Outcomes 2009, 7:25 http://www.hqlo.com/content/7/1/25
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graphic damage (p = 0.004) in RA. A similar association of
chronic comorbidity and high disease activity with AS,
peripheral PsA, and axial PsA were also found. Concern-
ing the mental component, an association was found in
RA with the disease activity (p < 0.0001), and in AS and
axial PsA with the low educational level (p level at < 0.001
and 0.009, respectively). The severity of psoriatic lesions
(assessed using PASI) was significantly associated with
poor mental functioning in patients with peripheral and
axial PsA (p level at < 0.0001 and 0.03, respectively).
Discussion
Patient-reported outcomes (PRO) are an attractive option
in a busy medical practice, as the time burden is trans-
ferred from the clinician to the patient [34]. The validity
and usefulness of PRO data in evaluating and monitoring
patients with IRD have been well documented [35,36].
PRO includes physical function or disability, pain, general
health status, side effects, medical costs and other content
areas. Inherent in the strategy of intensive treatment with
Disease Modyifing Anti-Rheumatic Drugs – DMARDs
(including biological agents) with the goal of preventing
or slowing permanent structural joint damage and long-
term disability in IRD is the accurate monitoring of HRQL
in daily practice and in clinical trials [37]. The SF-36 is, to
date, the most used tool that evaluates HRQOL as a sub-
jective perception about psychological and physical limi-
tations due to musculoskeletal disorders [38,39]. The
summary scales PCS and MCS were chosen to represent
HRQL in this study because they have been shown to be
among the most valid SF-36 scales for measuring physical
and mental health, respectively [40]. These scales are eas-
ier to administer and less expensive than physician-
observed disease activity and process measures [35,36].
The results of this study show that adults with IRD have
poorer self-reported health status than those without
arthritis in all domains of living, but particularly with
respect to scales measuring aspects of physical functioning
or mobility, role limitation due to physical health prob-
lems and usual activities, and bodily pain. The disease
with the worst HRQL for physical dimensions of SF-36
was RA. The mean PCS score for RA patients was 32.5,
approximately two standard deviations below the mean
observed in the Italian general population [25,38]. Based
on the PCS scores alone, the physical functioning of these
patients is comparable to patients with congestive heart
failure [40-42]. This results was similar in men and
women. Concerning patients with PsA and AS, our data
confirms clinical cohort studies from Germany [22],
United Kingdom [43], Turkey [44], and Canada [13], that
found similar functional disability and reduced HRQL in
patients with PsA compared to RA. Although patients with
PsA reportedly had lower levels of physical disability by
the SF-36 PCS, in comparison with health controls, they
also reported more psychosocial problems than patients
with RA and AS. Overall, the SF-36 MCS dimensions typ-
ically affected by PsA were mental health, limitations due
to emotional health, and social functioning. The extent of
disability among these patients may be attributed to the
fact that these patients have an inflammatory skin condi-
tion as well as peripheral and/or axial joint disease
[11,13]. The psychological and social effects of skin
involvement have been well documented in patients with
psoriasis [45,46]. In a survey by the National Psoriasis
Foundation almost 75% of patients believed that psoriasis
had moderate to large negative impact on their quality of
life, with alterations in their daily activities [47]. Further-
more, physical and emotional affects of psoriasis were
found to have a significant negative impact at patients'
workplace. Fortune et al. [48] identified that pathological
worry and anxiety occur in at least a third of patients with
psoriasis and that psychological interpersonal difficulties
impinge on all aspects of the patient's daily life. Other
studies reported that between 5 and 20 percent of psoria-
sis patients had contemplated suicide [49,50]. When com-
pared with patients with other diseases, such as cancer,
arthritis, hypertension, heart disease, diabetes, and
depression, patients with psoriasis reported a similar
reduction in HRQL [42,51]. According to Chorus, et al.
[45], we found that the physical component scores were
more favourable in AS than in RA. However, there was a
Comparison of Medical Outcomes Short Form-36 health sur- vey domain scores between patients with inflammatory rheu- matic diseases (IRD) and general population normative data Figure 1
Comparison of Medical Outcomes Short Form-36 
health survey domain scores between patients with 
inflammatory rheumatic diseases (IRD) and general 
population normative data. Higher scores represent bet-
ter health status. Physical functioning (PF), Role function – 
Physical aspect (RP), Bodily Pain (BP), General health percep-
tion (GH), Mental Health (MH), Role function – Emotional 
aspect (RE), Social functioning (SF), and Vitality (VT).Health and Quality of Life Outcomes 2009, 7:25 http://www.hqlo.com/content/7/1/25
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sex related difference: women reported lower scores than
men in role limitations due to physical function and in
general health subscales. These results were consistent
with a previous study of Dagfinrud, et al. [52].
The findings of the multivariate analysis suggests that the
SF-36 PCS scores may reflect both functional limitations
due to current disease activity due to processes that do not
respond to aggressive treatment with anti-rheumatic drugs
and limitations due to the radiographic damage and coex-
isting conditions. Kirwin [53], similarly, concluded that
disease activity remains the major determinant of disabil-
ity in RA, both late in disease and in patients with substan-
tial radiographic damage. Similarly, in psoriatic patients,
the results of Husted, et al. [12] support the view that the
disease activity was a significant predictor of physical
functioning, as measured by the Health Assessment Ques-
tionnaire (HAQ) over the course of PsA, although its effect
diminished over time.
The outcomes of a chronic condition may be also affected
by coexisting chronic conditions. It is important to incor-
porate assessment of comorbidity into studies involving
HRQL outcomes for persons with multiple chronic medi-
cal conditions, as coexisting conditions may substantially
affect outcomes of interest such as physical functioning,
overall health status, depression and response rates in ran-
domized controlled trials [53-55]. Our patients accurately
reported a majority of common comorbid conditions
respect to the general population. In particular, 53.7% of
our RA patients reported at least one comorbid condition,
which is in accord with the studies of Rupp, et al. (56%)
[56]. Berkanovic, et al. (54%) [57] and Gabriel, et al.
(49.3%) [58]. Similarly, AS and PsA were associated with
a variety of extra-articular manifestations that can result in
a number of comorbid conditions. Comparison of the
prevalence of comorbidity in these conditions remains,
therefore, difficult, however, because the definition of
comorbidity and the number of comorbid conditions
included varied between the studies, and different comor-
bidity measures were used in all studies. Many comorbid-
ity instruments were developed for hospitalized patients
to adjust for mortality rates. These instruments may have
Table 2: Mean ± SD (standard deviation) and 95% CI (confidence intervals) SF-36 scores in patients and the general population*
Groups
Rheumatoid arthritis
(n = 469)
Ankylosing spondilitis
(n = 164)
Peripheral PsA
(n = 101)
Axial PsA
(n = 65)
General population
(n = 1579)
Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI
PF 41.8 ± 20.6 39.9–43.6 52.6 ± 21.2 49.4–55.9 43.5 ± 21.4 39.3–47.7 50.6 ± 18.6 46.0–55.2 82.5 ± 20.0 81.9–83.9
RP 29.8 ± 16.0 28.3–31.2 38.2 ± 29.7 33.6–42.8 34.3 ± 27.3 28.9–39.7 38.4 ± 26.8 31.8–45.1 73.1 ± 36.7 71.3–74.9
BP 30.1 ± 17.0 28.5–31.6 45.0 ± 17.4 42.3–47.7 36.3 ± 17.9 32.7–39.8 45.9 ± 16.9 41.8–50.1 78.5 ± 20.8 77.5–79.6
GH 44.0 ± 19.7 42.3–45.8 47.2 ± 22.6 43.7–50.7 45.1 ± 16.8 41.8–48.5 43.8 ± 16.4 39.8–47.9 60.1 ± 18.1 59.3–61.0
MH 50.3 ± 23.3 48.2–52.4 54.3 ± 20.8 51.1–57.5 44.7 ± 18.0 41.2–48.3 47.6 ± 20.6 42.5–52.7 63.6 ± 16.8 62.9–64.5
RE 38.2 ± 41.4 34.4–41.9 42.0 ± 27.5 37.7–46.2 28.0 ± 29.7 22.1–33.9 37.6 ± 27.4 30.8–44.4 72.1 ± 38.1 70.2–73.9
SF 46.9 ± 21.3 45.0–48.8 54.7 ± 20.9 51.5–58.0 43.1 ± 19.2 39.3–46.9 44.7 ± 11.9 41.7–47.7 71.6 ± 20.1 70.6–72.7
VT 41.9 ± 20.8 40.1–43.8 48.5 ± 18.6 45.6–51.4 45.1 ± 15.8 42.0–48.3 41.8 ± 19.2 37.0–46.5 56.8 ± 15.4 56.2–57.7
SF-36 PCS 32.5 ± 6.0 31.9–33.0 37.1 ± 8.6 35.7–38.4 34.1 ± 6.9 32.8–35.5 37.5 ± 7.0 35.8–39.2 49.6 ± 8.9 49.2–50.2
SF-36 MCS 39.4 ± 11.8 38.3–40.5 40.7 ± 9.5 39.2–42.1 36.9 ± 6.8 35.5–38.3 36.5 ± 8.0 34.5–38.5 45.6 ± 8.4 43.1–46.1
*All differences between patients and the general population were significant at p < 0.0001.
Abbreviations: Physical functioning (PF), Role function – Physical aspect (RP), Bodily Pain (BP), General health perception (GH), Mental Health 
(MH), Role function – Emotional aspect (RE), Social functioning (SF), Vitality (VT), component summary scores of physical (PCS) and mental 
functioning (MCS)
Standard difference scores (s-scores) for patients with rheu- matoid arthritis, ankylosing spondylitis, peripheral PsA and  axial Psa Figure 2
Standard difference scores (s-scores) for patients 
with rheumatoid arthritis, ankylosing spondylitis, 
peripheral PsA and axial Psa. The values of the s-scores 
were interpreted according to Cohen's effect size index, in 
which 0.2 refers to a small difference, 0.5 to a moderate dif-
ference, and 0.8 or more to a large difference. Physical func-
tioning (PF), Role function – Physical aspect (RP), Bodily Pain 
(BP), General health perception (GH), Mental Health (MH), 
Role function – Emotional aspect (RE), Social functioning 
(SF), and Vitality (VT), component summary scores of physi-
cal (PCS) and mental functioning (MCS).Health and Quality of Life Outcomes 2009, 7:25 http://www.hqlo.com/content/7/1/25
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Table 3: SF-36 subscales and summary scores in patients and the controls by age groups. Data are expressed as means ± SD and 95% CI
AGE Group (years)
18 – 34 years 35 – 44 years 45 – 64 years 65 – 74 years > 75 years
Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI
PF
Controls 94.7 ± 10.9 93.4–96.0 91.8 ± 12.1 90.2–93.4 86.6 ± 15.6 85.3–88.0 74.8 ± 19.2 72.5–77.2 65.0 ± 22.7 62.5–67.5
RA 40.0 ± 17.1 34.2–42.7 41.0 ± 18.9 36.2–45.8 41.9 ± 20.7 39.9–45.0 40.6 ± 21.4 36.9–44.3 38.7 ± 21.2 33.2–44.1
SA 47.0 ± 20.3 28.2–65.7 53.5 ± 18.3 47.0–60.0 54.6 ± 20.5 50.5–58.6 49.7 ± 27.7 35.5–63.9 30.0 ± 17.6 11.5–48.5
Per PsA 75.0 ± 10.8 57.8–92.2 59.0 ± 23.1 42.5–75.5 41.5 ± 20.5 34.8–48.1 41.0 ± 20.8 33.7–48.2 35.3 ± 13.9 27.3–43.4
Ax PsA 72.5 ± 16.4 62.2–82.8 58.9 ± 19.5 44.0–73.9 48.3 ± 19.8 40.7–55.8 45.0 ± 14.7 38.3–51.7 62.5 ± 23.5 30.7–94.3
RP
Controls 88.6 ± 24.9 85.6–91.5 85.6 ± 24.5 82.4–88.8 78.6 ± 33.3 75.7–81.6 61.3 ± 38.4 56.6–66.1 51.8 ± 40.4 47.4–56.3
RA 29.3 ± 11.7 22.4–30.2 28.2 ± 15.3 24.3–32.1 29.5 ± 16.0 28.2–32.9 29.7 ± 16.9 27.8–3.7 28.0 ± 17.1 24.6–33.5
SA 46.4 ± 36.6 12.5–80.2 47.1 ± 24.8 38.3–55.9 35.3 ± 28.9 29.5–41.0 44.1 ± 38.0 24.5–63.6 32.5 ± 19.6 30.8–36.8
Per PsA 56.2 ± 31.4 16.1–86.3 47.5 ± 27.5 27.8–67.1 30.5 ± 28.1 21.4–39.6 29.0 ± 26.3 19.8–38.2 41.6 ± 20.6 29.7–53.5
Ax PsA 50.0 ± 20.4 17.5–82.4 50.0 ± 35.3 22.8–77.1 33.6 ± 26.1 23.6–43.5 35.2 ± 21.3 25.5–45.0 66.5 ± 47.3 29.1–72.1
BP
Controls 89.2 ± 15.1 87.3–90.9 80.4 ± 16.2 78.3–82.5 80.4 ± 19.6 78.7–82.1 68.9 ± 21.3 66.3–71.6 72.0 ± 23.4 69.4–74.6
RA 27.8 ± 14.0 24.1–32.4 27.7 ± 16.3 23.6–31.8 28.9 ± 18.4 26.2–34.6 29.9 ± 15.4 27.2–32.6 30.5 ± 17.2 26.1–34.9
SA 43.0 ± 28.1 16.9–69.0 47.2 ± 15.7 41.7–52.8 44.9 ± 16.5 41.6–48.1 49.8 ± 17.3 40.9–58.7 32.0 ± 18.3 27.9–36.0
Per PsA 43.1 ± 10.7 26.1–60.1 40.7 ± 17.3 28.3–53.1 35.8 ± 17.8 30.0–41.6 35.4 ± 20.2 28.4–42.5 34.3 ± 17.9 25.7–42.9
Ax PsA 53.7 ± 10.9 36.4–71.0 54.3 ± 27.2 33.3–75.2 46.2 ± 17.0 39.7–52.6 40.1 ± 10.4 35.3–44.8 40.0 ± 19.0 37.5–43.5
GH
Controls 74.3 ± 15.1 72.5–76.1 62.7 ± 19.7 60.1–65.3 61.9 ± 16.5 60.5–63.4 53.6 ± 14.8 51.8–55.4 49.1 ± 15.5 47.4–50.8
RA 44.3 ± 20.9 39.2–49.2 42.5 ± 15.3 38.6–46.5 46.3 ± 20.4 43.3–49.3 41.4 ± 18.8 38.1–44.6 39.7 ± 20.5 34.5–45.0
SA 50.6 ± 32.2 20.8–80.3 52.5 ± 24.5 43.8–61.2 46.1 ± 19.9 42.1–50.0 50.1 ± 27.1 36.1–64.0 23.3 ± 18.0 14.3–42.3
Per PsA 60.0 ± 19.1 45.4–74.5 53.5 ± 12.2 44.7–62.2 48.4 ± 18.1 42.5–54.3 41.0 ± 13.0 36.4–45.5 35.7 ± 18.9 24.7–46.6
Ax PsA 68.7 ± 13.1 47.8–89.6 52.2 ± 13.4 41.8–62.5 40.3 ± 14.3 34.8–45.7 40.7 ± 16.8 33.0–48.3 40.0 ± 14.1 27.0–67.0
MH
Control 71.6 ± 12.8 70.0–73.1 62.0 ± 14.3 60.1–63.8 64.2 ± 16.3 62.8–65.7 59.8 ± 17.2 57.7–61.9 58.7 ± 18.2 56.7–60.7
RA 44.1 ± 24.3 35.9–52.2 53.6 ± 21.4 48.1–59.0 53.2 ± 23.0 49.8–56.7 45.8 ± 22.0 42.0–49.6 51.6 ± 26.1 44.9–58.3
SA 48.0 ± 28.7 21.4–74.5 55.9 ± 22.4 47.9–63.8 54.5 ± 19.9 50.5–58.4 55.5 ± 20.0 45.1–65.8 46.6 ± 20.3 25.3–68.0
Per PsA 39.0 ± 22.9 12.4–75.5 44.4 ± 25.6 26.0–62.7 43.3 ± 16.8 37.9–48.8 45.4 ± 16.9 39.5–51.3 48.8 ± 17.9 38.4–59.2
Ax PsA 49.0 ± 18.0 20.3–77.6 59.6 ± 19.0 45.0–74.2 43.7 ± 20.8 35.7–51.6 47.6 ± 19.0 38.9–56.3 48.0 ± 45.2 28.5–54.5
RE
Controls 85.3 ± 28.6 81.8–88.6 82.6 ± 30.1 78.6–86.5 80.7 ± 28.8 78.2–83.2 51.5 ± 41.5 46.4–56.6 54.8 ± 43.3 50.1–59.6
RA 47.7 ± 41.2 33.9–61.4 38.1 ± 42.1 27.4–48.8 39.5 ± 42.4 33.3–45.8 32.0 ± 38.5 25.3–38.7 41.2 ± 42.7 30.2–52.2
SA 46.5 ± 43.0 16.6–86.2 47.2 ± 28.6 37.0–57.3 40.2 ± 26.6 34.9–45.4 41.6 ± 27.9 27.2–55.9 38.7 ± 13.7 24.3–53.1
Per PsA 24.8 ± 16.5 20.3–51.1 46.6 ± 42.1 16.4–76.7 25.6 ± 26.8 16.9–34.3 24.4 ± 28.8 14.4–34.5 30.9 ± 30.5 13.2–48.5
Ax PsA 33.3 ± 47.1 21.6–58.3 48.0 ± 24.3 29.2–66.7 40.7 ± 27.3 30.3–51.1 28.5 ± 24.2 17.4–39.5 50.0 ± 24.0 36.0–66.0
SF
Controls 78.2 ± 18.7 75.9–80.4 73.6 ± 19.6 71.1–76.2 72.7 ± 19.3 71.0–74.4 68.1 ± 19.9 65.6–70.6 66.0 ± 20.8 63.7–68.3
RA 38.1 ± 20.4 31.3–44.9 47.9 ± 19.1 43.1–52.8 50.7 ± 22.4 47.4–54.0 43.3 ± 20.1 39.8–46.8 47.5 ± 21.1 42.0–52.9
SA 51.4 ± 35.4 18.6–84.1 58.7 ± 22.6 50.7–66.8 54.0 ± 18.5 50.3–57.6 60.2 ± 21.7 49.1–71.4 33.2 ± 17.0 15.3–51.1
Per PsA 53.2 ± 29.3 16.6–79.8 44.9 ± 10.6 37.3–52.4 39.7 ± 20.9 32.9–46.5 44.1 ± 20.9 36.8–51.4 35.5 ± 19.3 32.1–43.8
Ax PsA 56.1 ± 21.7 21.4–90.8 51.2 ± 22.1 34.2–68.2 42.5 ± 7.1 39.8–45.3 42.7 ± 27.5 39.3–46.2 33.5 ± 19.1 30.0–42.0
VT
Controls 62.4 ± 13.4 60.8–64.0 54.2 ± 15.5 52.2–56.3 57.7 ± 14.8 56.4–59.0 55.1 ± 15.2 53.3–57.0 53.6 ± 16.6 51.8–55.5
RA 31.6 ± 18.7 25.3–37.8 46.2 ± 19.5 41.2–51.1 44.6 ± 20.9 41.5–47.7 38.9 ± 20.9 35.3–42.6 42.2 ± 19.7 37.2–47.3
SA 45.0 ± 23.9 22.8–67.1 52.4 ± 20.4 45.1–59.6 47.8 ± 17.2 44.4–51.2 49.7 ± 20.4 39.2–60.2 39.1 ± 21.7 16.3–62.0
Per PsA 50.0 ± 18.1 35.4–64.5 55.0 ± 14.3 44.7–65.2 44.4 ± 16.4 39.1–49.8 41.7 ± 15.9 36.1–47.3 46.7 ± 13.8 38.8–54.7
Ax PsA 63.7 ± 33.5 10.4–87.0 49.4 ± 15.7 37.3–61.5 39.8 ± 15.5 33.9–45.7 36.4 ± 18.2 28.1–44.7 47.5 ± 38.8 31.9–66.9
SF-36 PCS
Controls 54.9 ± 5.6 53.2–55.6 52.7 ± 6.1 51.9–53.5 50.8 ± 8.1 50.1–51.5 46.8 ± 8.2 45.8–47.8 43.8 ± 8.1 42.9–44.7
RA 32.3 ± 4.4 29.8–34.8 31.3 ± 5.4 29.9–32.7 31.5 ± 6.3 32.5–34.4 32.9 ± 6.0 30.8–34.9 31.0 ± 5.3 29.6–32.3
SA 37.6 ± 10.3 27.9–47.1 38.7 ± 8.5 35.7–41.7 37.0 ± 7.4 35.6–38.5 37.9 ± 12.3 31.6–44.2 24.8 ± 5.9 18.6–31.0
Per PsA 46.0 ± 3.3 40.7–51.2 37.7 ± 7.0 32.7–42.7 33.4 ± 6.7 31.2–35.6 33.2 ± 6.9 30.8–35.7 32.0 ± 3.5 30.0–34.0
Ax PsA 47.2 ± 3.2 42.0–52.4 40.3 ± 7.8 34.3–46.4 36.4 ± 6.6 33.9–38.9 35.4 ± 5.4 32.9–37.9 42.0 ± 13.4 28.4–62.4
SF-36 MCS
Controls 47.7 ± 6.9 46.9–48.5 46.6 ± 6.7 45.7–47.5 46.3 ± 7.2 45.7–46.9 43.0 ± 9.4 41.8–44.1 43.6 ± 9.5 42.5–44.6
RA 40.6 ± 9.9 37.3–43.9 40.1 ± 11.4 37.2–44.0 40.7 ± 12.3 38.8–42.5 38.7 ± 10.7 36.8–40.6 38.6 ± 13.1 36.2–41.0
SA 39.0 ± 13.8 26.2–51.8 42.1 ± 11.1 38.1–46.0 40.2 ± 8.4 38.5–41.9 41.6 ± 10.9 35.9–47.2 38.9 ± 8.7 29.8–48.1
Per PsA 32.9 ± 4.5 25.7–40.0 40.6 ± 9.6 33.7–47.5 36.3 ± 6.1 34.3–38.3 36.0 ± 6.3 33.8–38.2 38.9 ± 7.3 34.7–43.2
Ax PsA 37.0 ± 6.7 26.3–47.7 41.0 ± 9.5 33.7–48.4 35.7 ± 7.4 32.9–38.6 35.3 ± 6.9 32.2–38.5 36.3 ± 12.6 27.0–42.7
Abbreviations: RA = Rheumatoid arthritis, SA = Ankylosing spondylitis, Per PsA = Peripheal Psoriatic arthritis, Ax PsA = Axial Psoriatic arthritisHealth and Quality of Life Outcomes 2009, 7:25 http://www.hqlo.com/content/7/1/25
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Table 4: SF-36 subscales and summary scores in patients and the controls with primary school, secondary school and high school/
university. Data are expressed as means ± SD and 95% CI
Eucational level
Primary school Secondary school High school/university
Mean SD 95% CI Mean SD 95% CI Mean SD 95% CI
PF
Controls 75.4 21.8 73.8 – 77.1 89.3 14.1 88.1 – 90.5 91.4 13.0 89.4 – 93.3
RA 39.2 20.5 35.7 – 42.7 40.4 20.5 37.9 – 42.9 50.0 19.1 45.8 – 54.3
SA 51.0 25.5 43.1 – 58.9 52.6 17.0 47.4 – 57.8 55.9 18.9 45.8 – 66.0
Per PsA 42.3 24.9 33.0 – 51.6 42.0 18.9 37.3 – 46.7 55.0 19.3 25.0 – 75.0
Ax PsA 44.6 17.4 34.9 – 54.3 52.3 19.3 46.1 – 58.5 56.1 12.9 46.1 – 66.0
RP
Control 65.5 38.3 62.6 – 68.4 80.8 32.1 78.0 – 83.5 83.8 30.3 79.4 – 88.3
RA 28.5 13.6 27.2 – 31.9 29.1 15.9 26.1 – 31.1 35.3 18.9 31.0 – 39.5
SA 33.1 33.2 28.9 – 49.3 39.6 25.9 30.7 – 46.5 54.6 31.9 37.6 – 71.6
Per PsA 23.6 25.4 14.1 – 33.0 37.3 25.3 31.0 – 43.5 68.7 37.5 19.0 – 88.4
Ax PsA 33.3 30.8 16.2 – 50.4 36.2 23.7 28.6 – 43.8 58.3 27.9 36.8 – 79.8
BP
Controls 72.3 21.6 70.6 – 73.9 84.2 17.5 82.7 – 85.8 86.1 15.9 83.8 – 88.5
RA 29.3 17.8 27.3 – 33.3 30.3 16.4 27.3 – 32.4 31.6 17.3 27.7 – 35.5
SA 42.6 18.1 38.0 – 49.2 43.9 12.8 39.0 – 46.8 53.5 19.6 43.0 – 63.9
Per PsA 39.5 20.3 31.9 – 47.1 33.4 16.2 29.4 – 37.4 53.1 18.1 24.1 – 82.0
Ax PsA 35.1 14.5 27.0 – 43.2 46.4 13.5 42.1 – 50.8 64.1 18.8 49.6 – 78.6
GH
Controls 55.2 18.2 53.8 – 56.6 64.3 17.9 62.7 – 65.8 68.9 14.8 66.7 – 71.1
RA 40.9 19.1 37.7 – 44.2 44.3 19.5 41.8 – 46.7 48.1 20.2 43.6 – 52.6
SA 45.2 22.5 38.3 – 52.2 45.4 20.8 39.0 – 51.7 57.2 21.3 45.8 – 68.6
Per PsA 44.6 16.0 38.6 – 50.6 45.5 17.8 41.1 – 49.9 48.7 2.5 44.7 – 52.7
Ax PsA 38.6 15.2 30.1 – 47.1 44.8 17.9 39.1 – 50.6 48.3 9.6 40.8 – 55.7
MH
Controls 59.8 16.9 58.5 – 61.1 66.7 15.5 65.3 – 68.0 66.6 15.4 64.3 – 68.9
RA 48.8 24.2 44.7 – 52.9 49.8 23.1 46.9 – 52.6 54.2 22.0 49.3 – 59.1
SA 42.9 19.4 36.9 – 48.9 52.9 16.9 47.7 – 58.0 66.70 13.7 59.4 – 74.0
Per PsA 46.4 13.8 41.2 – 51.5 43.6 19.7 38.7 – 48.5 44.0 11.3 25.9 – 62.0
Ax PsA 39.2 22.2 26.8 – 51.5 48.7 20.1 42.2 – 55.1 54.7 17.1 41.6 – 67.9
RE
Controls 63.2 40.5 60.1 – 66.3 79.3 33.2 76.4 – 82.2 79.4 31.0 74.9 – 84.0
RA 35.7 42.5 31.4 – 45.9 38.8 40.0 33.8 – 43.8 44.1 43.3 34.5 – 53.8
SA 33.3 26.5 25.1 – 41.4 40.1 26.0 32.2 – 48.0 77.1 31.5 60.2 – 93.9
Per PsA 21.0 25.4 11.5 – 30.5 31.2 27.0 22.5 – 32.9 28.9 31.9 25.8 – 35.6
Ax PsA 31.0 26.6 16.2 – 45.8 41.2 28.8 31.9 – 50.4 53.2 23.6 41.0 – 61.3
SF
Controls 68.4 19.8 66.9 – 69.9 74.6 20.2 72.9 – 76.3 77.4 18.2 74.7 – 80.1
RA 44.7 21.0 41.1 – 48.3 47.2 21.6 44.5 – 49.9 48.8 20.2 44.3 – 53.3
SA 46.9 19.0 41.1 – 52.8 52.2 19.5 46.2 – 58.1 75.6 19.7 65.1 – 86.1
Per PsA 44.6 19.5 37.2 – 51.9 41.5 18.6 36.9 – 46.1 62.5 17.6 34.3 – 90.6
Ax PsA 39.0 8.0 34.6 – 43.5 45.8 10.8 42.3 – 49.3 49.8 18.8 35.4 – 64.3
VT
Controls 55.1 15.4 53.9 – 56.2 58.8 15.7 57.4 – 60.1 57.7 14.1 55.6 – 59.8
RA 39.4 20.6 35.9 – 42.9 41.9 20.9 39.3 – 44.5 45.8 20.1 41.4 – 50.3
SA 40.9 20.8 34.5 – 47.3 48.2 15.9 43.4 – 53.1 54.6 11.1 48.7 – 60.6
Per PsA 47.6 15.1 41.9 – 53.3 43.6 16.4 39.5 – 47.6 48.7 10.3 32.3 – 65.1
Ax PsA 29.3 19.0 18.7 – 39.8 45.0 18.6 39.0 – 50.9 47.2 15.2 35.5 – 58.9
SF-36 PCS
Controls 47.2 8.7 46.5 – 47.9 52.2 7.2 51.6 – 52.8 53.6 5.4 52.8 – 54.4
RA 31.7 5.9 30.7 – 32.7 32.2 5.8 31.4 – 32.9 34.5 6.2 33.1 – 35.8
SA 36.1 9.9 34.1 – 40.2 38.4 6.5 35.4 – 41.4 38.3 9.8 33.0 – 43.5
Per PsA 33.4 8.1 30.4 – 36.4 33.6 5.2 32.3 – 34.9 48.4 5.0 40.3 – 56.5
Ax PsA 35.0 6.0 31.6 – 38.3 37.5 7.1 35.2 – 39.7 43.0 4.2 39.8 – 46.2
SF-36 MCS
Controls 44.1 8.3 43.4 – 44.7 47.1 7.9 46.4 – 47.7 46.5 7.4 45.4 – 47.6
RA 38.8 12.1 36.7 – 40.8 39.2 11.5 37.7 – 40.6 40.8 12.0 38.1 – 43.5
SA 34.8 7.4 32.5 – 37.1 39.9 7.9 37.5 – 42.3 50.4 8.8 45.7 – 55.1
Per PsA 37.1 4.7 35.3 – 38.8 37.0 7.6 35.1 – 38.9 31.7 6.6 21.1 – 42.4
Ax PsA 32.5 8.7 27.6 – 37.3 37.6 7.6 35.1 – 40.0 40.9 7.3 35.3 – 44.6
For definitions see Table 3Health and Quality of Life Outcomes 2009, 7:25 http://www.hqlo.com/content/7/1/25
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limitations in adjusting for functional status as an out-
come. Measures of comorbidity typically use information
from the medical record or administrative data. These
approaches impose limitations, such as the availability of
medical records and the quality of documentation.
Research has shown that patients can accurately assess
their current and past medical conditions including
comorbidities [59,60]. The SCQ, that added items about
treatment (as a surrogate for disease severity) and func-
tional limitation. represents an efficient method to assess
comorbid conditions in clinical and health services
research [32].
Of the demographic factors studied, education level had
the most important association with negative impact on
patients' mental HRQL among patients with chronic pain-
associated disability. Despite its recognized importance in
health outcomes, education level and other measures of
socioeconomic status have been infrequently examined as
predictors of quality of life in IRD. Lower levels of formal
education have been reported to be a risk factor for pres-
ence of chronic musculoskeletal pain and physical func-
tion in the community and has been associated with a
higher prevalence of work disability and greater disease
activity in patients with AS and RA [9,38]. The mechanism
by which education influences pain disability or psycho-
logical process is unclear but may be related to enhanced
self-efficacy and sense of control allowing the patient to
take advantage of a greater number of pain reducing
modalities. Our findings suggest that educational level
may have a greater effect on mental health outcomes in AS
and axial PsA.
This study has several limitations that should be taken
into account in interpreting the results. First, it is based in
a tertiary referral Centre and patients with more severe
IRD may be overrepresented. These results may, therefore,
not be generalizable to all patients with IRD in the com-
munity. In addition, recall periods for the various meas-
ures differed. This discrepancy in recall time is common
when using multiple self-report measures and is inherent
in the measures. However self-report data are a valuable
resource, and the problems encountered with self-report
data are similar to those encountered in other forms of
data collection. Second, the cross-sectional design limits
the analysis about the associated factors with physical
function and HRQL and does not allow to draw final con-
clusions about the strengths of the cause-effect relation-
ships. The most of the literature on this issue are cross-
sectional studies and not suited for statement or implica-
tions. Further, selection bias cannot be excluded. How-
ever, the relatively large group of patients was aged
between 20 and 82 years, and the whole range of disease
activity, physical functioning, and radiographic damage
scores was represented, indicating a representative group
of IRD patients.
Conclusion
Despite to the limitations discussed above, our study con-
firms that the physical aspects of health seem to be most
severely affected in patients with IRD although all dimen-
sions of health were significantly affected, and in the PsA
group of patients, the disease impact on mental health
was considerable. A management programme for patients
with IRD and the planning of the healthcare services
should take these findings into account by maintaining
the focus on impairment and physical function, but also
focusing on the mental and social consequences of the
disease. Longitudinal studies are, also, needed to examine
how these quality of life measures change over time and
respond to clinical and public health interventions.
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